Could Andrographolide from Andrographis Paniculata help with multiple sclerosis?

reference

Ciampi e, Uribe-San-Martin R, Carcamo C, et al. Effectiveness of Andrographological with non -active progressive multiple sclerosis: a prospective, exploratory, double -blind, randomized, placebo -controlled parallel group study. BMC Neurol . 2020; 20 (1): 1-10.

Study goal

to determine whether a pure Andrographolid compound (AP) was extracted Andrographis Paniculata could reduce brain atrophy and the progress of the disability with non-active progressive multiple sclerosis

draft

A 24-month, double-blind, placebo-controlled, randomized study in a single location in Chile

Intervention

The Andrographolid Group received 140 mg Andrographolid (99.5 % purity) orally twice a day for 24 months. The placebo group received identical control.

participant

There were 44 patients (24 women, 20 men) who were randomized for this study, and 37 (24 women, 13 men) participants who ended the study. Of the 37 participants, 17 were in the placebo group and 20 in the AP group.

All patients were older than 18 years (mean = 58 years old for the placebo group and 59 years for the AP group) and had the diagnosis of non-active, primary or secondary, progressive MS in accordance with the criteria of McDonald 2010. They had no evidence of relapses or new brain lesions last year. All patients had an initial value on the Expanded Disability Status Scale (EDSS) of less than 8.0 and a value on the Mini Mental State Exam (MMSE) of more than 24.

The exclusion criteria included patients with a thrust -like remitting MS or active (clinically or radiologically) progressive MS to use the use of glucocorticoids 3 months before the study or immunomodulatory drugs for 6 months before the study, uncontrolled medical or psychiatric illnesses and pregnancy or invalidity.

study parameters evaluated

Clinical disability was assessed every 12 weeks by a blinded test doctor who pursued the values ​​on the EDSS and on the Multiple Sclerosis Functional Composite (MSFC).

At the start of the course and after 24 months, a whole brain MRI was carried out. The thickness of the retinal fiber nerve layer was estimated at the start of the study and after 24 months.

This study assessed changes in the progression of the disability. To quantify this, various measures were used, including:

• Medium change in the retinal nerve fiber layer thickness measured with optical coherence tomography (OTC)
• Medium change in a time-controlled 25-footed test (T25WT), a 9-hole-peg test (9HPT), the Digit Modalities Test (SDMT) symbol, the Fatigue Severity Scale (FSS), the multiple sclerosis IMPACT SCALE (MSIS29) and the Beck-Depreis inventory (BDI)

primary result measurements

The primary endpoint was the difference of the average percentage change in the brain volume (MPBVC), measured by means of an MRI at the beginning of the course and after 2 years.

important knowledge

Although the primary result of the percentage change in the brain volume did not achieve statistical significance, two other secondary result dimensions achieved statistical significance. A significant reduction in brain atrophy in the AP group compared to the placebo group was found (36.5 %, measured with Siena, and 75 % Post Hoc, measured with BPF, p = 0.033). The percentage of patients with a 12-week confirmed disability progression also showed a statistically significant acceptance in the AP group to the placebo group (HR = 0.596; 95 % KI: 0.2000–1.777).

practice implications

Andrographis Paniculata traditionally used to treat inflammation and bacterial infections. It is believed that the most active component is Andrographolid, a Diterpenoid. It was found that Andrographolid has antifetting, anti -cancer, anti -diabetics and anti -inflammatory effects to name just a few. ^{1 Clinically I observed that persistent Lyme disease and co -infections represent themselves as complex symptom constellation in connection with unchecked inflammation channels. In my practice, tinctures of the above -ground parts from Andrograpis Paniculata (usually together with other plants) were a valuable player in the fight against the inflammation caused by Lyme disease. In view of my history with this plant, I did not surprise me that the presumed active ingredient could improve the symptoms and slow down the progression of the MS.}

In my experience, there are considerable overlaps between diseases and MS transferred by ticks. I saw several patients in whom MS was diagnosed and who had a significant improvement in their MS symptoms when an illness underlying was treated by ticks. Has the MS worsened by the disease transmitted by ticks? Did the disease transmitted by tick cause the MS? Was MS really a misdiagnosis? It is everyone's assumption. Regardless of this, I recommend examining your MS patients for diseases transferred through ticks. You may be pretty surprised by what you find.